Biosimilars Market Regional Analysis and Emerging Growth Factors from 2021-2025

According to reports, the U.S. is slated to drive key significance in North America biosimilars market. It is suggested that the market is projected to gain considerable growth at a rate of more than 38.1% over the forecast period. This could be given to the presence of state-of-art technologies and facilities for biosimilar product development, and existence of reputed and well-established companies. The U.S. FDA’s nod on biosimilars in 2015 would also result in rapid product adoption, which may thereby stimulate North America biosimilars market outlook.

Biosimilars have found increasing application in the hematology sector. Reports claims that, in 2018, the hematology segment recorded revenues worth around USD 4552.1 million. Rising cases of blood disorders like anemia and neutropenia is expected to supplement product adoption. The American Society of Hematology claims that, in the U.S., approx. 3 million people suffer from anemia. With such growing prevalence, the biosimilars market is poised to record substantial proceeds from the hematology industry.

Request for a sample copy of this report @

Technological advancements in high-throughput analytical techniques and cell technology may support the effective production of drugs. Introduction of insulin glargine in major countries and surging demands of filgrastim may aid biosimilars industry expansion.

In terms of product, the biosimilars market is divided into recombinant non-glycosylated proteins and recombinant glycosylated proteins. Of the two, recombinant non-glycosylated proteins market was reported to hold a majority share in the global biosimilars market in the year 2018. Studies suggest that the segment is likely to grow at more than 26.1% over the forecast period.

The ability to assess and monitor production and reduce shipping and delivery costs has encourage companies to conduct in-house manufacturing of biosimilars. Efficiency and flexibility of the work and generation of enhanced financial and operational capabilities have lured manufactures to opt for in-house biosimilar production. Growing shift towards such manufacturing techniques may shape biosimilars market outlook. As a matter of fact, in 2018, the in-house manufacturing segment held for around 75% of the market share.

Several Indian pharmaceutical companies, supported by their experience in manufacturing generics, are beginning to make a move into the global biosimilars market. Reliable reports claim that most Indian pharmaceutical firms are beginning to accrue a substantial percentage of their revenue from biosimilars. This has, in consequence, provided a major impetus to the regional biosimilars industry statistics.

The future of India biosimilars market is often reflected in the way global pharmaceutical companies forge partnerships with Indian firms. The most notable one is the agreement between U.S. pharma company Mylan N.V. and India’s Biocon. The partnership has seen substantial progress in obtaining approvals for biosimilars across Europe and the U.S in 2018, which helped Biocon witness a 36% revenue growth – approximately $120 million – through its biosimilars business.

In addition to the U.S., presence of companies like Biogen, Amgen, Celltrion, Boehringer Ingelheim, Coherus BioSciences and more might foster global biosimilars market size. Firms like these are targeting less addressed and highly potential regions to expand their business presence. Development and introduction of new biosimilar drugs by major companies in developing nations may augment the overall biosimilars industry growth.

Request for customization @

Partial Chapter of the Table of Content

Chapter 6.    Biosimilars Market, By Manufacturer

6.1. Global market share by manufacturer, 2018 & 2025

6.2. Contract Research and Manufacturing Services

6.2.1.    Market size, by region, 2014 – 2025 (USD Million)

6.3. In-house

6.3.1.    Market size, by region, 2014 – 2025 (USD Million)

Chapter 7.    Biosimilars Market, By Technology

7.1. Global market share by technology, 2018 & 2025

7.2. Recombinant DNA Technology (rDNA technology)

7.2.1.    Market size, by region, 2014 – 2025 (USD Million)

7.3. Monoclonal Antibodies (MAb) Technology

7.3.1.    Market size, by region, 2014 – 2025 (USD Million)

Browse full table of contents (TOC) of this report @